Gene Editing Market

The gene editing market is expected to reach USD 7.59 billion in 2029 from USD 4.66 billion in 2024, at a CAGR of 10.2% during the forecast period. The main factors behind the expansion of this market are demand for personalized medicine, and favorable government funding investments for gene editing projects. The expanding range of gene editing applications, spurred by technological advancements in prime editing, bridge RNA and the growing burden of congenital diseases, are also contributing to the market's expansion.

The gene editing market is competitive with key players such Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), GenScript (US), Agilent Technologies, Inc. (US), Revvity (US). The market players have adopted various strategies such as development of advanced products, services, partnerships, contracts, expansions, and acquisitions to strengthen their position in the gene editing market. The organic and inorganic strategies have helped the market players expand globally by providing advanced gene editing products and services.

To know about the assumptions considered for the study download the pdf brochure

Thermo Fisher Scientific Inc. (US)

Thermo Fisher Scientific Inc. provides an extensive portfolio of life science solutions, analytical instruments, diagnostics, and laboratory services for many applications. The company offers a comprehensive portfolio of gene editing products and services, encompassing tools, services, and software for gene modification. The company provides gene editing tools and services via the Genetic Sciences and Biosciences business within the life sciences solutions segment. The company has executed organic and inorganic growth strategies, launching products such as the Gibco CTS AAV-MAX Helper-Free AAV Production System in November 2022, establishing a manufacturing facility at the University of California, San Francisco in March 2023, and acquiring gene editing companies like PeproTech, Inc. (US) in January 2022.

Merck KGaA (Germany)

Merck KGaA is a healthcare-focused research and technology company. The company offers gene editing technologies and services through the Science & Lab Solutions subsegment of the Life Sciences segment. Sigma Aldrich and Milliporesigma are the brand names under which the firm distributes its gene editing solutions. The firm has a global reach through its subsidiaries and brands. The company expanded inorganically by acquiring Mirus Bio, Inc. (US) in May 2024 and forming a partnership with Synplogen Co., Ltd. (Japan) in December 2022.

GenScript (US)

Genscript is a biotechnology company that provides life science research application instruments and services. The company operates in the gene editing market through the Life Science Services and Products segment which  provides comprehensive life-science research services and products. The company operates in over 100 countries through various subsidiaries. GenScript (US) pursued organic growth with the launch of FLASH Gene in June 2024 and expansion of gene synthesis services in Singapore in February 2023, while also forming an inorganic partnership with PersonGen-Anke Cellular Therapeutics (US) in March 2023 to enhance cell therapy development.

Agilent Technologies, Inc. (US)

Agilent Technologies, Inc. is a life sciences, diagnostics, and applied chemicals company that offers instruments, software, consumables and services for entire laboratory workflow. The company offers gene editing products and services through the diagnostics and genomics business segment. The company has several subsidiaries spanning across all major regions. The company strengthened inorganically by acquiring BIOVECTRA, Inc. (Canada) in July 2024 and collaborating with Merck KGaA (Germany) in June 2022 to advance process technologies and organically by expansion of a manufacturing facility in China in August 2021.

Revvity (US)

Revvity is a health science solutions company that focuses on technology and services ranging from research to development and diagnosis. Revvity provides a variety of products and services in the Life Sciences segment, including gene editing products and services, to help with cell, gene, and protein studies. Revvity distributes its products and services in over 160 countries. Revvity pursued organic growth by launching its pin-point base editing platform reagents in September 2023, while inorganic growth was achieved through collaborations with GenKOre (South Korea) in June 2023 and a partnership with AstraZeneca Plc (UK) in May 2023, which involved licensing their services to develop advanced gene therapies.

Related Reports:

Gene Editing Market by Product (Kits, Reagents, Libraries, Software), Services (gRNA Synthesis & Vector Construction), Technique (Knock-Out, Knock-In), Technology (CRISPR, ZFN, TALEN), Application (Genome Editing, Drug Discovery) - Global Forecast to 2029

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]